X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9293) 9293
Publication (1341) 1341
Book Review (391) 391
Book Chapter (24) 24
Conference Proceeding (18) 18
Dissertation (5) 5
Book / eBook (3) 3
Magazine Article (3) 3
Data Set (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8621) 8621
animals (5667) 5667
extracellular signal-regulated map kinases - metabolism (5393) 5393
humans (4972) 4972
phosphorylation (3061) 3061
mice (2755) 2755
signal transduction (2505) 2505
extracellular signal-regulated kinase (2449) 2449
extracellular signal-regulated map kinases - antagonists & inhibitors (2206) 2206
rats (2202) 2202
male (2088) 2088
cell biology (1983) 1983
cells, cultured (1889) 1889
signal transduction - drug effects (1809) 1809
activation (1794) 1794
cell line, tumor (1791) 1791
kinases (1722) 1722
apoptosis (1600) 1600
expression (1590) 1590
proteins (1514) 1514
biochemistry & molecular biology (1511) 1511
phosphorylation - drug effects (1380) 1380
female (1366) 1366
oncology (1254) 1254
map kinase (1242) 1242
cell line (1194) 1194
cell proliferation - drug effects (1139) 1139
enzyme inhibitors - pharmacology (1125) 1125
neurosciences (1121) 1121
map kinase signaling system - drug effects (1107) 1107
protein kinase inhibitors - pharmacology (1101) 1101
proto-oncogene proteins c-akt - metabolism (1089) 1089
gene expression (1064) 1064
cancer (1062) 1062
apoptosis - drug effects (1018) 1018
rats, sprague-dawley (967) 967
research article (950) 950
rodents (938) 938
article (933) 933
cell proliferation (916) 916
medicine (880) 880
erk (876) 876
pharmacology & pharmacy (874) 874
blotting, western (872) 872
multidisciplinary sciences (851) 851
inhibition (843) 843
dose-response relationship, drug (825) 825
cells (824) 824
p38 mitogen-activated protein kinases - metabolism (816) 816
research (791) 791
science (781) 781
enzyme activation - drug effects (770) 770
inflammation (759) 759
physiology (755) 755
enzyme activation (749) 749
gene-expression (738) 738
flavonoids - pharmacology (734) 734
analysis (709) 709
activated protein-kinase (694) 694
signaling (657) 657
in-vitro (652) 652
phosphatidylinositol 3-kinases - metabolism (649) 649
mice, inbred c57bl (647) 647
signal transduction - physiology (641) 641
time factors (640) 640
protein kinases (639) 639
proliferation (624) 624
immunology (608) 608
physiological aspects (608) 608
nitriles - pharmacology (600) 600
cell survival - drug effects (597) 597
mitogen-activated protein kinases - metabolism (582) 582
butadienes - pharmacology (574) 574
biology (567) 567
map kinase signaling system (547) 547
pathway (529) 529
oxidative stress (528) 528
biochemistry (518) 518
growth (503) 503
transfection (495) 495
nf-kappa-b (494) 494
nf-kappa b - metabolism (493) 493
rna, messenger - metabolism (492) 492
extracellular signal-regulated map kinases - physiology (489) 489
cytokines (483) 483
extracellular signal-regulated map kinases - genetics (483) 483
neurons (483) 483
mitogen-activated protein kinase 1 - metabolism (482) 482
p38 mitogen-activated protein kinases - antagonists & inhibitors (482) 482
disease models, animal (478) 478
map kinase signaling system - physiology (477) 477
in-vivo (476) 476
akt protein (473) 473
receptors (470) 470
receptor (467) 467
pathways (466) 466
jnk mitogen-activated protein kinases - metabolism (463) 463
antineoplastic agents - pharmacology (460) 460
health aspects (459) 459
endocrinology & metabolism (456) 456
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9248) 9248
Chinese (48) 48
French (4) 4
Japanese (4) 4
Russian (3) 3
German (2) 2
Spanish (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Discovery, ISSN 2159-8274, 07/2013, Volume 3, Issue 7, pp. 742 - 750
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 8, pp. 2316 - 2325
Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We... 
COLON-CANCER | METASTATIC MELANOMA | PIK3CA MUTATIONS | PI3K | ONCOLOGY | COLORECTAL-CANCER | RESISTANCE | BRAF | ANTITUMOR-ACTIVITY | MEK INHIBITORS | TUMORS | Neoplasms - metabolism | Extracellular Signal-Regulated MAP Kinases - drug effects | TOR Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Male | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - genetics | Proto-Oncogene Proteins c-akt - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | MAP Kinase Signaling System - genetics | TOR Serine-Threonine Kinases - genetics | Neoplasms - genetics | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | MAP Kinase Signaling System - drug effects | Proto-Oncogene Proteins B-raf - genetics | Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors | Adolescent | Aged | Mutation | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Journal Article
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7315, pp. 596 - 599
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the... 
ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | MUTATION | KERATOACANTHOMAS | SENSITIVITY | SENESCENCE | SORAFENIB | HUMAN CANCER | PROGRESSION | BRAF(V600E) | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Macaca fascicularis | Melanoma - enzymology | Substrate Specificity | Positron-Emission Tomography | Extracellular Signal-Regulated MAP Kinases - metabolism | Indoles - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Phosphorylation - drug effects | Mutant Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Sulfonamides - chemistry | Mutant Proteins - genetics | Models, Molecular | Rats | Mutant Proteins - metabolism | Melanoma - pathology | Mutation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Indoles - adverse effects | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutant Proteins - chemistry | Alleles | Dogs | Sulfonamides - adverse effects | Indoles - therapeutic use | Indoles - chemistry | Sulfonamides - administration & dosage | Control | Gene mutations | Melanoma | Development and progression | Genetic aspects | Research | Health aspects | Protein kinases | Cancer | Proteins | Mutation | Kinases | Rodents | Index Medicus | targeted therapy | melanoma | BRAF | PLX4032 | biomarker | oncogene
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 05/2014, Volume 25, Issue 5, pp. 697 - 710
MEK inhibitors are clinically active in BRAF melanomas but only marginally so in KRAS mutant tumors. Here, we found that MEK inhibitors suppress ERK signaling... 
LUNG-CANCER | CELLS | MELANOMA | ONCOLOGY | KINASE | C-RAF | IMPROVED SURVIVAL | BRAF | B-RAF | MUTATIONS | FEEDBACK INHIBITION | CELL BIOLOGY | Surface Plasmon Resonance | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Diphenylamine - pharmacology | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Melanoma - enzymology | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | MAP Kinase Kinase 1 - chemistry | MAP Kinase Kinase 1 - genetics | Diphenylamine - analogs & derivatives | RNA Interference | Melanoma - genetics | TNF Receptor-Associated Factor 3 - genetics | HEK293 Cells | Indoles - pharmacology | Pyrimidinones - pharmacology | Benzamides - pharmacology | Phosphorylation - drug effects | Cell Line | MAP Kinase Kinase 1 - antagonists & inhibitors | Proto-Oncogene Proteins - genetics | TNF Receptor-Associated Factor 3 - metabolism | Sulfonamides - pharmacology | Coumarins - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Pyridones - pharmacology | Analysis | Melanoma | Tumors | Index Medicus
Journal Article
Cell, ISSN 0092-8674, 04/2012, Volume 149, Issue 2, pp. 307 - 321
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 02/2015, Volume 352, Issue 2, pp. 346 - 357
Journal Article
Cancer Research, ISSN 0008-5472, 12/2009, Volume 69, Issue 24, pp. 9228 - 9235
Journal Article
Nature, ISSN 0028-0836, 06/2012, Volume 486, Issue 7401, pp. 80 - 84
The complexity of cancer has led to recent interest in polypharmacological approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition... 
PATHWAYS | RET | CHROMOSOME | DROSOPHILA MODEL | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | CELL-PROLIFERATION | PD-0325901 | INHIBITOR | SORAFENIB | CARCINOMA | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-ret - metabolism | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Male | Phenylurea Compounds | Extracellular Signal-Regulated MAP Kinases - metabolism | Protein Kinase Inhibitors - adverse effects | Drosophila Proteins - metabolism | Molecular Targeted Therapy | Drosophila melanogaster - genetics | Heterocyclic Compounds, 4 or More Rings - pharmacology | Multiple Endocrine Neoplasia Type 2b - genetics | Multiple Endocrine Neoplasia Type 2b - enzymology | Benzenesulfonates - pharmacology | Multiple Endocrine Neoplasia Type 2b - drug therapy | Protein Kinase Inhibitors - chemistry | Polypharmacy | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Drug-Related Side Effects and Adverse Reactions | src-Family Kinases - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Drug Evaluation, Preclinical | Drosophila Proteins - antagonists & inhibitors | Disease Models, Animal | src-Family Kinases - antagonists & inhibitors | Heterocyclic Compounds, 4 or More Rings - chemistry | Heterocyclic Compounds, 4 or More Rings - adverse effects | Survival Rate | Drosophila melanogaster - drug effects | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Cell Transformation, Neoplastic - drug effects | Drosophila Proteins - genetics | Cell Transformation, Neoplastic - pathology | Proto-Oncogene Proteins c-ret - genetics | Chemotherapy | Physiological aspects | Genetic aspects | Cellular signal transduction | Research | Carcinogenesis | Risk factors | Cancer | Proteins | Nuclear magnetic resonance--NMR | Insects | Toxicity | Mutation | Kinases | Drug dosages | Cell adhesion & migration | Index Medicus
Journal Article
Science, ISSN 0036-8075, 02/2017, Volume 355, Issue 6327, pp. 836 - 842
Journal Article